CME Portlet 2011
#tabbed_box_2_cme { margin: 0px auto 0px auto; } #tabbed_box_2_cme .tabbed_area_cme { padding:8px; } #tabbed_box_2_cme ul.toolstabs { margin:2px 0 7px; padding:0px; } #tabbed_box_2_cme ul.toolstabs li { list-style:none; display:inline; margin: -3px; } #tabbed_box_2_cme ul.toolstabs li a { background-color:#1d6ee1; color:#ffffff; padding: 1em; text-decoration:none; font-size:9px; font-family:Verdana, Arial, Helvetica, sans-serif; font-weight:bold; background-repeat:repeat-x; background-position:bottom; border:1px black solid; text-align: center; } #tabbed_box_2_cme ul.toolstabs li a:hover { background-color:#0d2d5a; /*border-color:#2f343a;*/ } #tabbed_box_2_cme ul.toolstabs li a.active { background-color:#144892; color:#ffffff; /*border-bottom: 1px solid #ffffff;*/ background-repeat:repeat-x; background-position:top; border-bottom:none; margin-bottom:1px; padding-bottom:10px; } .content2_cme { background-color:#ffffff; padding:10px 10px 10px 5px; font-family:Arial, Helvetica, sans-serif; background-repeat:repeat-x; background-position:bottom; margin-top: 6px; margin-left: -3px; border:1px solid #87837E; } #acontent_cme_2 { display:none; } .content2_cme ul { margin:0px; padding:0px 20px 0px 20px; } .content2_cme ul li { list-style:square; color:#1d6ee1; /*border-bottom:1px solid #d6dde0;*/ padding-top:5px; padding-bottom:5px; font-size:13px; } .content2_cme ul li:last-child { border-bottom:none; } .content2_cme ul li a { text-decoration:none; color:#3e4346; } .content2_cme ul li a small { color:#8b959c; font-size:9px; font-family:Verdana, Arial, Helvetica, sans-serif; position:relative; left:4px; top:0px; } .content2_cme ul li a:hover { color:#a59c83; } .content2_cme ul li a:hover small { color:#baae8e; } #_career_outer { border-color:#87837E #87837E; border-style:none solid solid; border-width:medium 1px 1px 1px; margin-left: -3px; } #_career_inner { background:#8fccf0 none repeat scroll 0 0; margin:0px 5px 5px 5px; padding-bottom:10px; padding-top:10px; }
Newsletter
Access practical, evidence-based guidance to support better care for our youngest patients. Join our email list for the latest clinical updates.
Andrew Alexis, MD, MPH, highlights positive lebrikizumab-lbkz data for atopic dermatitis
June 25th 2025Lebrikizumab demonstrated efficacy and safety in patients with skin of color and moderate-to-severe atopic dermatitis in the ADmirable trial. Trial investigator Andrew Alexis, MD, MPH, reacts.
